CEVEC Grants Licence to Biotest for Production of Tailor-Made Glycoproteins

CEVEC Pharmaceuticals has granted a licence for its proprietary CAP Go technology to Biotest for the development, production and commercialization of candidate molecules to treat the symptoms of hemophilia patients.

Under the terms of the license agreement, CEVEC will receive service fees for ongoing development support, upfront and milestone payments as well as royalties on future product sales.

"With Biotest, we have found an important partner for our unique CAP(R)Go expression system," commented Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH. "We consider Biotest's commitment as a significant endorsement of our CAP Go technology."